We collected data retrospectively from July 2019 to March 2022. We included all NSCLC patients at our hospital who were: (1 (link)) age 18 years or older, (2 (link)) pathologically confirmed, (3) clinical stage IB–IIIC, and (4) underwent neoadjuvant immunochemotherapy followed by surgery. The exclusion criteria were as follows: (1) previous immunotherapy, (2) no available pretreatment CT scans, (3) non-measurable lesions per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, (4) poor image quality that was not suitable for feature extraction, and (5) a biopsy was performed prior to the available CT. Patient clinicopathological information, including age, sex, stage, PD-L1 expression (Dako 22C3), and details about their neoadjuvant treatment, including agents and course of treatment, were collected from the electronic database. MPR was defined as 0-10% of viable tumor cells remaining in the residual tumor.
Dako 22c3
Manufactured by Agilent Technologies
The Dako 22C3 is a laboratory instrument designed for the detection of the PD-L1 protein in tumor samples. It is used in the evaluation of PD-L1 expression, which is a biomarker associated with certain types of cancer. The Dako 22C3 provides quantitative analysis of PD-L1 expression levels, supporting clinical decision-making processes.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using dako 22c3
1
Neoadjuvant Immunochemotherapy for NSCLC
2
Pembrolizumab for PD-L1 Low Solid Tumors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients were enrolled from May 31, 2018, to October 07, 2020. Treatment with pembrolizumab at a flat dose of 200 mg was administered intravenously every 3 weeks (21±3 days) and continued until 2 years or 35 cycles (whichever occurred later) or until documented disease progression, unacceptable toxicity or withdrawal of the patient’s consent. Tumor response was assessed every 9 weeks (63±3 days) according to the Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1. PD-L1 expression was centrally assessed during the screening phase by immunohistochemistry with the anti-PD-L1 antibody (DAKO 22C3) on archival or newly obtained tumor-biopsy specimens (within 45 days prior treatment initiation) and only patients with a PD-L1 TPS expression <50% were eligible. Baseline tumor tissue was used for RNA immune gene-expression profiling. Blood samples were collected at baseline, every two cycles, and at the end of treatment for circulating immune profiling analysis. Stool samples were collected at baseline, after the first cycle and at the end of treatment.
3
Multimodal Profiling of Tumor Samples
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Fine needle aspiration specimens were obtained from each patient before initiation of systemic treatment. Immunohistochemistry was performed to detect the expression of PD-L1 using Dako 22C3 (Dako Monoclonal Mouse Anti-Human PD-L1, Clone 22C3) on tumor biopsy samples. PD-L1 expression was evaluated using isolated tumor cells and certified by a senior pathologist in our hospital. Whole exon sequencing (WES) was conducted using the SureSelect Human All Exon V6 kit (Agilent, Santa Clara, CA, USA). Genomic alterations, including microsatellite stability status, single base substitutions, short and long insertions/deletions (INDELS), copy number variants, and gene rearrangement and fusions, were assessed. Tumor mutation burden (TMB) was determined by analyzing somatic mutations including coding base substitutions and INDELs according to the megabase (Mb).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!